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Objective: Endograft infection after thoracic endovascular aortic repair (TEVAR) is associated with a substantial mortality
rate that exceeds 70% in the largest published series. The aim of this study was to review all published reports on infection
after TEVAR treated with either preservation of the endograft or surgical excision of the stent graft with the intention of
providing a comparison of the safety, efﬁcacy, and durability of the two different treatment strategies.
Methods: An extensive electronic health database search was undertaken to identify all articles that were published up to
December 2013 reporting on endograft infection after TEVAR. Overall, 55 patients treated with endograft preservation
(group A) and 41 patients treated with endograft explantation (group B) were included in this review.
Results: The most frequently isolated microorganisms were Streptococcus species (29.4%) and Staphylococcus species (29.4%).
The mortality for both groups was 66.6%. The in-hospital mortality rate in group A was 42% and reached 81.8% in a mean
follow-up period of 8.6 months. The in-hospital mortality rate in group B was 36.6%. Four (9.7%) further deaths due to
reinfection or ﬁstula recurrence were recorded in a mean follow-up period of 15.3 months, leading to an overall mortality
of 46.3%. The meta-analysis showed a trend of better outcome with endograft explantation compared with endograft
preservation (odds ratio [OR], 0.52; 95% conﬁdence interval [CI], 0.18-1.48). In group A, a trend of better outcome was
revealed when drainage and repair of the ﬁstula were applied (OR, 2.22; 95% CI, 0.55-8.90). A trend of worse outcomes
was detected in ﬁstula patients compared with nonﬁstula patients (OR, 1.26; 95% CI, 0.43-3.74).
Conclusions: Endograft preservation seems not a durable option. It can be offered to patients who refuse surgery or as a
palliative option or bridging procedure for severely ill patients. Compared with antibiotic therapy alone, antibiotic therapy
followed by drainage and repair of the ﬁstula may control the sepsis, providing, however, mainly a temporary beneﬁt. The
presence of ﬁstula is a predictor of dismal outcome. Endograft explantation remains the “gold standard” of treatment. The
mortality rate of surgical conversion is much higher in the presence of ﬁstula. (J Vasc Surg 2014;60:1061-71.)An endograft infection after thoracic endovascular aortic infection that portends signiﬁcantly worse prognosis.3,6-8repair (TEVAR) is a dramatic event and has been character-
ized fairly as the nightmare of cardiovascular surgeons. As
TEVAR has become a well-accepted alternative to tradi-
tional open surgery because of the low perioperative compli-
cation rate, thoracic endograft infections are increasing in
frequency. Thoracic endograft infections range from 1.53%
to 4.77%1,2 and are associated with a considerable mortality
rate that exceeds 70% in the largest published series.3-5
Aortoesophageal ﬁstula (AEF) or aortobronchial ﬁstula
(ABF) is a common presentation of a thoracic endograftthe Department of Vascular Surgery, Athens University Medical
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://dx.doi.org/10.1016/j.jvs.2014.07.012The presence of ﬁstula between the thoracic aorta and
the mediastinum organs has, on the one hand, the poten-
tial of acute exsanguination and, on the other, the poten-
tial of continuous contamination of the circulation with
microorganisms that put the patient in a constant septic
condition.1
The “gold standard” of treatment for endograft infec-
tions remains total endograft explantation with arterial
reconstruction, débridement, and repair of the ﬁstula if pre-
sent.7-9 This is a demanding operation with high morbidity
and mortality rates that many patients may not tolerate
because of severe comorbidities.7-10 Preservation of the
endograft followed by appropriate antibiotic therapy,
drainage or débridement, and repair of the ﬁstula has
been described as an alternative treatment in selected
high-risk patients who are unﬁt for open repair.6,8,10-12
The aim of this article was to review all published re-
ports on infection after TEVAR treatment with either pres-
ervation of the endograft or surgical excision of the stent
graft and aortic reconstruction. The eligible reports are pre-
sented in an extensive analysis with the intention of1061
Fig 1. Flow chart of studies included in the review analysis.
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two different treatment strategies.
METHODS
An extensive electronic health database search was un-
dertaken to identify all the articles that were published up
to December 2013 reporting on endograft infections after
endovascular repair of thoracic aortic disease, treated either
with endograft explantation and aortic reconstruction or
with the preservation of the endograft. Publications were
retrieved by electronic search engines (MEDLINE,
EMBASE, Scopus, Google Scholar, Ovid, and the
Cochrane Library). The following keywords were used:
“endograft infection,” “TEVAR infection,” “endograft
explantation,” “preservation of the endograft,” “conserva-
tive treatment,” “aortoesophageal ﬁstula, aortobronchial
ﬁstula.” In addition, the reference lists of all retrieved arti-
cles were examined for further relevant studies. Articles in
languages other than English were excluded. Reports on
primary AEF or ABF treated with open repair or secondary
AEF or ABF after open repair of thoracic aortic diseases
treated with prosthetic graft explantation were also
excluded. When multiple publications on the same pa-
tient sample were identiﬁed or study populations over-
lapped, only the latest report was included unless the
reported outcomes were mutually exclusive. Because of
the paucity of large series and to increase our understand-
ing and to gain depth in this dramatic and potentially le-
thal disease, we also included case reports in the review
analysis. This decision was based on the fact that thoracic
infection is a relatively rare and unpredictable event for
which population-based studies or randomized trials are
difﬁcult or even unethical to be organized.
Each study was reviewed by two independent reviewers
(S.N.M. and K.G.M.), and the following data were
extracted: number of patients, index indication of endovas-
cular procedure, time interval from TEVAR to the diagnosisof the infection, clinical presentation of endograft infection,
antibiotic agents administered, treatment strategy followed,
outcome, and follow-up period. If discrepant results were
obtained, the articles were reanalyzed by the two reviewers
and consensus was reached. Standard descriptive statistics
(reported as mean with 95% conﬁdence interval [CI])
were used to summarize numerical data.
Furthermore, with the intention of increasing the
robustness of our review, we have conducted three separate
odds ratio (OR) meta-analyses of all eligible series in accor-
dance with the recommendations of the Meta-analysis of
Observational Studies in Epidemiology group13:
1. Endograft explantation vs endograft preservation;
2. Additional treatment vs none in patients treated with
endograft preservation; and
3. Presence of ﬁstula vs absence of ﬁstula.
The meta-analyses were performed with Stata 12 statis-
tical software (Stata Corp LP, College Station, Tex). The
outcome in all OR meta-analyses was the overall mortality
rate, and the results are reported as forest plots.
RESULTS
The electronic search returned 61 citations (ﬂow chart,
Fig 1). Seventeen studies were discarded at the title/abstract
level, whereas three more were excluded after inclusion
criteria application. In particular, a single study14 including
patients from multiple centers was excluded from the pre-
sent review as many of the recruited patients were described
previously in separate, more detailed publications with indi-
vidualized data. Overall, 21 studies3,4,6,9,15-31 (six retrospec-
tive cohort studies/case series, 15 case reports) with a total
of 55 patients with thoracic endograft infection treated
with endograft preservation (group A, Tables I and II)
and 20 studies3,5-8,10-12,15,25,26,32-40 (seven retrospective
cohort studies/case series, 13 case reports) with a total of
Table I. Indication for index procedure, clinical presentation, additional procedures, follow-up, and outcome in case
series of patients treated with preservation of the endograft
Author No.
Age,
gender
Indication for
index procedure
Interval
from index
procedure,
months
Clinical
presentation
In addition to
antibiotic treatment
Follow-up,
months Outcome
Lyons et al,4
2013
9 43 Pseudoaneurysmal
degeneration of graft
5 (mean) Constitutional
symptoms
Drain 15 Death
68 Infected
pseudoaneurysm after
open repair of a type
III TAAA
ABF Bovine patch, left lower
lobectomy, thoracic
window
45 Death
72 TAA ABF TEVAR and
percutaneous drainage
10 Death
75 Infected
pseudoaneurysm after
open TAAA repair
Constitutional
symptoms
None 1 Death
63 AEF after open TAA
repair
Constitutional
symptoms
None 13 Death
69 AEF Constitutional
symptoms
TEVAR 1 Death
69 Cutaneous left
subclavian aneurysm
ﬁstula after
radiotherapy
Constitutional
symptoms
None 5 Death
75 Infected
pseudoaneurysm after
open thoracic
dissection repair
Constitutional
symptoms
None 53 Death
59 Mycotic TAA after
esophagectomy
Constitutional
symptoms
TEVAR and drainage 3 Death
Murphy et al,15
2013
4 ND ND ND Constitutional
symptoms
None 2 Death
Cernohorsky
et al,20 2011
2 ND Ruptured TAA 1 Constitutional
symptoms
Repeated TEVAR ND Alive
ND TAA 1 Constitutional
symptoms
None 4 Death
Chiesa et al,3
2010
16 75, M ND 10.9 (mean) AEF Repeated TEVAR Perioperative Death
82, F AEF Repeated TEVAR and
mediastinal drainage
Perioperative Death
70, M AEF Bipolar esophageal
exclusion
Perioperative Death
84, M AEF, ABF Bipolar esophageal
exclusion and
bronchial repair
6 Death
69, M AEF, ABF Cervical esophagostomy Perioperative Death
61, M AEF Esophagectomy and
gastric ‘‘pull-up’’
18 Alive
73, M AEF, ABF Esophageal stent grafting Perioperative Death
70, M AEF Esophageal stent grafting 5 Alive
78, M ABF None ND Death
78, M AEF
83, M AEF
80, M AEF
73, M AEF
75, M AEF, ABF
80, M AEF
68, M AEF
Eggebrecht
et al,25 2009
5 62, M AD 2 Recurrent
back pain
and fever,
AEF
None 3 Death
74, F TAA 9 New-onset
fever, AEF
PEG 10 Death
77, F Ruptured TAAA 3 Hematemesis,
fever, AEF
Esophageal stent
implantation, PEG
6 Death
67, F Acute AD 14 Hematemesis,
fever, AEF
Repeated TEVAR, PEG 8 Death
52, M Acute AD 5 Hematemesis,
AEF
Esophageal stent
implantation, PEG
1 Death
(Continued on next page)
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Table I. Continued.
Author No.
Age,
gender
Indication for
index procedure
Interval
from index
procedure,
months
Clinical
presentation
In addition to
antibiotic treatment
Follow-up,
months Outcome
Heyer et al,26
2009
4 66, M TAA 2 Constitutional
symptoms
None 2 weeks Death
60, M TAA 1.5 Constitutional
symptoms
None 2 weeks Death
72, F TAA 12 Constitutional
symptoms
None 10 days Death
46, F TAA 12 Constitutional
symptoms
None ND Alive
ABF, Aortobronchial ﬁstula; AD, aortic dissection; AEF, aortoesophageal ﬁstula; F, female; M, male; ND, not described; PEG, percutaneous endoscopic
gastrostomy; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm.
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Tables III and IV) were included in this review. Demo-
graphics and comparisons between the two groups are pre-
sented in Table V.
Diagnosis and clinical presentation of infection
The mean interval from the initial TEVAR procedure to
the diagnosis of the endograft infection was 12.9 months
(95% CI, 8.2-17.7) for group A and 15.7 months (95% CI,
5.6-25.8) for group B. The diagnosis of an endograft infec-
tion was based on a combination of clinical symptoms,
laboratory test results, and imaging studies. The clinical pre-
sentation varied from constitutional symptoms including
persistent fever, weight loss, and back or chest pain to hema-
temesis or hemoptysis indicative ofAEForABF. Inparticular,
AEFwas conﬁrmedwith imaging studies and upper gastroin-
testinal endoscopy in 47 (51.6%) patients (25 in group A and
22 in group B). ABF was found in 15 (15.6%) patients (six in
group A and nine in group B), whereas six (6.25%) patients
(four in group A and two in group B) developed con-
comitantly both AEF and ABF. A single patient presented
with hemodynamic collapse, necessitating cardiopulmonary
resuscitation, with documented migration of the stent graft
and rupture of the distal aortic arch/proximal descending
aorta.8 A single patient underwent an adjacent left subclavian
artery chimney stent because of symptoms of hand ischemia
before the development of the endograft infection.4
Microbiology
Data concerning bacterial cultivations were available in
25 patients (12 in group A and 13 in group B). These
cultivations refer to either blood samples or purulent col-
lections after computed tomographyeguided drainage.
Bacterial cultivations were negative in 32% of the patients
(four of 12 patients in group A, four of 13 patients in group
B). The most frequently isolated microorganisms were
Streptococcus species (29.4%) and Staphylococcus species
(29.4%); other bacteria cultivated were Candida albicans,
Pseudomonas aeruginosa, and Enterobacter cloacae (4%,
respectively). Furthermore, in four patients (16%), more
than one bacterial species was identiﬁed.Group A (endograft preservation)
All patients of group A were administered, on admis-
sion, intravenous broad-spectrum antibiotics, which were
later modiﬁed to a bacterial cultureeguided antibiotic ther-
apy. The endograft preservation was chosen as treatment
strategy because of either the patient’s poor clinical status
at the time of diagnosis or the surgeon’s preference. Pa-
tients of this group had an increased age on admission
compared with group B (mean, 69.6 vs 61.7). In almost
half of them (26 of 55), an additional procedure was per-
formed. In particular, a repeated TEVAR procedure with
the intention of endograft extension, surgical repair (ie,
esophagectomy, bronchial repair, and sac débridement
or bovine patch interposition), computed tomographye
guided percutaneous drainage combined or not with endo-
vascular or surgical procedures, and esophageal stenting
combined with percutaneous endoscopic gastrectomy
were applied (Tables I and II).
Group B (endograft explantation)
In six (14.6%) of the 41 patients of group B, an extra-
anatomic bypass was performed after endograft explanta-
tion, whereas the remaining 35 patients (85.4%) underwent
aortic reconstruction through an in situ synthetic (silver-
coated) graft or cryopreserved allograft (Tables III to V).
Esophagectomy, esophageal stenting, and lung resection
were adjunctive procedures. A single patient with ABF after
TEVAR was treated initially by pulmonary segmentectomy
and coverage of the endograft with the serratus muscle.
However, the patient was readmitted 4 months later
because of severe mediastinitis, revealing recurrence of a
stent graft infection. The stent graft was explanted, and
the descending thoracic aneurysm was repaired with a
silver-coated tube graft.6
Outcome and follow-up
The overall mortality for both groups was 66.6% (64 of
96) in a mean follow-up period of 11.7 months (95% CI,
6.8-21.3).
Group A (endograft preservation). The in-hospital
mortality rate in group A was 42%. In particular, 25
Table II. Indication for index procedure, clinical presentation, additional procedures, follow-up, and outcome in case
reports of patients treated with preservation of the endograft
Author
Age,
gender
Indication
for index
procedure
Interval from
index procedure,
months Clinical presentation
In addition
to antibiotic
treatment
Follow-up,
months Outcome
Onodera et al,16
2013
73, M AD 48 AEF Esophageal covered
stenting
1.7 Death
Canaud et al,6
2013
58, M AD 28 ABF Pulmonary
segmentectomy,
pleural ﬂap coverage
13 Alive
Muradi et al,17
2013
65, M TAAA 4 Persistent fever, AEF None 2 Death
Yamashita et al,18
2012
74, M TAA 48 Cold-like symptoms,
hemoptysis, ABF
None 1.2 Death
Akkoyunlu
et al,19 2012
67, M AD 84 Constitutional
symptoms
None 6 Alive
Motloch et al,9
2011
57, M Acute AD 12 Painful microembolic
lesions of the ﬁrst 2
digits of the right
hand
None 16 Alive
Numan et al,21
2011
68, M TAA ND Weight loss, back
pain, fever,
vomiting, AEF
Computed tomography
eguided drainage
4 Alive
Ishikawa et al,
201122
81, F Mycotic TAA 0.16 Hematemesis, AEF Coil embolization and
esophageal stenting
13 Death
Yavuz et al,23
2011
60, F ruptured TAA 48 Hematemesis, AEF Repeated TEVAR
(extension)
Perioperative Death
Gavens et al,24
2011
80, F Mycotic TAA 3 AEF None 1 Death
d’Ettorre et al,27
2009
61, M TAA ND Constitutional
symptoms
None ND Alive
Isasti et al,28
2009
74, M TAA 24 Weight loss,
anorexia, back
pain, fever,
melena, AEF
None 0.5 Death
Martens et al,29
2007
64, F TAA 3 AEF Cervical esophagectomy,
jejunostomy, catheter-
based irrigation of the
aneurysm
2.1 Death
Boeckler et al,30
2006
78, M Acute AD 18 ABF Coil embolization of the
false lumen
0.5 Death
Czerny et al,31
2005
57, M Ruptured TAA 1 Swallowing
disorders, chest
pain, fever, AEF
Esophagectomy, cervical
esophagostomy and a
feeding gastrostomy,
sac débridement
6 Alive
ABF, Aortobronchial ﬁstula; AD, aortic dissection; AEF, aortoesophageal ﬁstula; F, female; M, male; ND, not described; TAA, thoracic aortic aneurysm;
TAAA, thoracoabdominal aortic aneurysm.
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diagnosis of endograft infection, whereas 20 further pa-
tients died during a mean follow-up period of 8.6 months
(95% CI, 4.4-12.9), and overall mortality reached 81.8%. A
subgroup analysis was performed to further assess the role
of ﬁstula as a potential predictive factor that may affect the
outcomes. Among patients with a ﬁstula, either AEF or
ABF or both, the overall mortality rate was 85.7% (30 of 35
patients). The mortality in the subgroup of patients pre-
senting with constitutional symptoms, sepsis, and absence
of ﬁstula was 75.0% (15 of 20).
Group B (endograft explantation). The periopera-
tive mortality rate in group B was 36.6% (15 of 41 patients
of group B died perioperatively). Four (9.7%) further deaths
due to reinfection or ﬁstula recurrence were recorded
in a mean follow-up period of 15.3 months (95% CI,9.4-21.3), leading to an overall mortality of 46.3%. The
overall mortality rate in the subgroup of patients with
presence of ﬁstula (AEF or ABF or both) was 51.5% (17 of
33), whereas in patients with endograft infection and
absence of ﬁstula, it was 25% (two of eight patients). As
previously described, 35 patients underwent an in situ
reconstruction with either a silver-coated graft or a cry-
opreserved allograft and six patients with an extra-anatomic
bypass. Themortality rate in the in situ group was 42.8% (15
of 35 succumbed), whereas in patients with extra-anatomic
bypass, it was 66.7% (four of six patients died).
Meta-analyses results
We conducted three separate OR meta-analyses (Figs
2-4). The OR meta-analysis on endograft explantation vs
endograft preservation showed a trend of better outcome
Table III. Indication for index procedure, clinical presentation, treatment, follow-up, and outcome in case reports of
patients treated with explantation of the endograft
Author No.
Age,
gender
Indication for
index procedure
Interval from
index procedure,
months
Clinical
presentation Treatment
Follow-up,
months Outcome
Canaud et al,6
2013
4 75, M ABF after open
TAA repair
2 ABF Extra-anatomic ascending to
supraceliac abdominal aorta
bypass
Perioperative Death
86, F Ruptured TAA 18 AEF In situ aortic reconstruction
with tube graft (silver-coated
polyester graft),
esophagectomy
Perioperative Death
84, M TAA 11 ABF In situ aortic reconstruction
with graft (silver-coated
polyester graft), atypical lung
resection
13 Alive
70, M TAA 13 ABF Pulmonary segmentectomy,
serratus muscle ﬂap coverage;
4 months laterdmediastinitis,
endograft explantation, in situ
silver-coated tube graft
6 Alive
Fatima et al,7
2013
3 71, M TAA 3 Constitutional
symptoms
In situ aortic reconstruction
with rifampin-soaked graft
14 Alive
74, M TAA 93.8 Constitutional
symptoms
Perioperative Death
35, F TAA 1 ABF 6 Alive
Murphy
et al,15 2013
2 ND ND AEF In situ aortic reconstruction ND Alive
ND AEF Perioperative Death
LeMaire et al,5
2012
7 66, M ND ND AEF In situ reconstruction with
rifampin-soaked prosthetic
graft and esophagectomy
Perioperative Death
61, M ND ND ABF In situ reconstruction with
rifampin-soaked prosthetic
graft and débridement of lung
tissue
6.5 Death
56, M ND ND Constitutional
symptoms
In situ reconstruction with
rifampin-soaked prosthetic
graft
51.5 Alive
39, M ND ND Constitutional
symptoms
In situ reconstruction with
homograft
3 Death
65, M ND ND Constitutional
symptoms
In situ reconstruction with
rifampin-soaked prosthetic
graft
23 Alive
61, M ND ND ABF In situ reconstruction with
rifampin-soaked prosthetic
graft and débridement of lung
tissue
1.5 Death
69, M ND ND AEF In situ reconstruction with
rifampin-soaked prosthetic
graft and esophagectomy
3 Alive
Saito et al,34
2012
5 42, M Primary AEF 5 AEF In situ reconstruction with
cryopreserved allograft and
esophagectomy
54 Alive
71, M Ruptured TAA 2.6 AEF 12 Alive
83, M TAA 100.8 AEF 8.6 Alive
78, M Ruptured TAA 1 AEF 38 days Death
52, M TAA 0.13 AEF 2 Alive
Chiesa et al,3
2010
3 76, M ND ND AEF Extra-anatomic bypass Perioperative Death
69, M ND ND AEF In situ aortic reconstruction,
bipolar esophagectomy
Perioperative Death
58, F ND 14 AEF and ABF Esophagectomy, in situ aortic
reconstruction
30 Alive
Girdauskas
et al,8 2008
4 TAA 3.5 Recurrent
sepsis
In situ aortic reconstruction
with silver-coated tube graft
13.5 Alive
TAA 1.5 Hemodynamic
collapse
Extra-anatomic bypass 13.5 Alive
TAA 49 AEF In situ aortic reconstruction,
esophagectomy
39 days Death
Ruptured TAA 3.5 AEF In situ aortic reconstruction,
esophagectomy
13.5 Alive
ABF, Aortobronchial ﬁstula; AD, aortic dissection; AEF, aortoesophageal ﬁstula; F, female; M, male; ND, not described; TAA, thoracic aortic aneurysm.
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Table IV. Indication for index procedure, clinical presentation, treatment, follow-up, and outcome in case reports of
patients treated with explantation of the endograft
Author
Age,
gender
Indication for
index procedure
Interval from
index procedure,
months
Clinical
presentation Treatment
Follow-up,
months Outcome
Munakata et al,32
2013
38, M AD 3 AEF In situ reconstruction with
rifampin-soaked Dacron
graft and esophagectomy
24 Alive
Kay et al,33 2013 79, M Ruptured TAA ND AEF Extra-anatomic bypass 2 Death
De Masi et al,10
2013
44, M TAA 0.3 AEF Extra-anatomic bypass and
esophageal deﬁcit oversewn
36 Alive
Lee et al,35 2012 50, F Ruptured
pseudoaneurysm
3 AEF Endograft explantation and in
situ aortic reconstruction
with rifampin-soaked graft
9 days Death
Franco Garcia
et al,36 2012
TAAA ND ABF In situ aortic reconstruction
with cryopreserved aortic
allograft
ND Alive
Riesenman
et al,37 2010
52, M Pseudoaneurysm
after anterior
spinal fusion
33 ABF Ascending to descending
thoracic aortic bypass
18 Alive
Kim et al,38 2010 75, M Ruptured TAA 4 AEF and
ABF
In situ aortic reconstruction,
direct closure of the
lacerated esophagus and
bronchus, and wrapping
visceral pleura around the
grafted aorta
20 days Death
Heyer et al,26
2009
62, M TAA 24 Periaortic
abscess
In situ aortic reconstruction
with rifampin-soaked graft
12 Alive
Eggebrecht
et al,25 2009
49, M Acute AD 2 AEF In situ aortic reconstruction
with Dacron graft,
esophageal stent
implantation
2 Death
Riesenman
et al,11 2007
52, M TAA 1.5 AEF Closure of the esophageal
defect, in situ aortic
reconstruction with
rifampin-soaked Dacron
graft
25 days Death
Porcu et al,39
2005
59, M AD 1 AEF Esophageal drainage and
extra-anatomic bypass
4 days Death
Hance et al,12
2003
24, F Traumatic thoracic
aortic transection
15 AEF In situ aortic reconstruction
and closure of the
esophageal defect
15 Alive
VonFricken
et al,40 2000
72, M Pseudoaneurysm
after open
TAAA repair
30 ABF In situ aortic reconstruction Intraoperative Death
ABF, Aortobronchial ﬁstula; AD, aortic dissection; AEF, aortoesophageal ﬁstula; F, female; M, male; ND, not described; TAA, thoracic aortic aneurysm;
TAAA, thoracoabdominal aortic aneurysm.
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1.48). Among the eligible studies on endograft preserva-
tion, the OR meta-analysis detected a trend of better
outcome in patients treated with antibiotic therapy followed
by additional procedures, such as mediastinal drainage, re-
peated TEVAR, and repair of the ﬁstula (esophageal stenting
or esophagostomy), compared with patients treated with
antibiotic therapy alone (OR, 2.22; 95% CI, 0.55-8.90). In
our meta-analysis, a trend of worse outcomes in ﬁstula pa-
tients was detected compared with nonﬁstula patients (OR,
1.26; 95% CI, 0.43-3.74). In addition, we investigated
whether the type of reconstruction was associated with a bet-
ter outcome. No trend or statistical difference was observed
regarding the type of reconstruction (extra-anatomic vs in
situ reconstruction).DISCUSSION
The results of our study showed that management
based on preservation of the endograft was associated
with a substantial increase in hospital mortality; 42.8% of
the patients succumbed during the hospitalization, whereas
39.8% of group A patients died during the follow-up
period, resulting in an overall mortality of 81.8%. Although
no statistical signiﬁcance was reached, a trend toward bet-
ter outcome in terms of overall mortality was found when
additional procedures, such as mediastinal drainage,
repeated TEVAR, esophageal stenting or esophagostomy
or esophageal exclusion, or bronchial repair, were per-
formed compared with antibiotic treatment alone (OR,
2.22; 95% CI, 0.55-8.90). In a recent review analysis of
endograft infection after endovascular repair of abdominal
Fig 2. Comparison of outcome among patients treated with endograft explantation and endograft preservation. CI,
Conﬁdence interval; Ev/Trt, events/treated with endograft explantation; Ev/Ctrl, events/control (endograft
preservation).
Table V. Demographic data and comparisons between the two groups
Endograft preservation (group A) Endograft explantation (group B)
Series Case reports Total Series Case reports Total
No. of publications 6 15 21 7 13 20
No. of patients 40 15 55 28 13 41
Gender 19 M, 6 F, 15 Nr 1 M, 4 F 30 M, 10 F, 15 NR 19 M, 3 F, 6 NR 10 M, 2 F, 1 NR 29 M, 5 F, 7 NR
Age, years, mean (95% CI) 69.6 (66.3-73.0) 67.8 (63.1-72.4) 69.6 (67.1-72.2) 65.5 (59.3-71.7) 54.6 (44.6-64.8) 61.7 (56.3-67.0)
Indication for index procedure
TAA 9/40 8/15 17/55 14/28 6/13 20/41
AEF or ABF (primary or after
open repair)
2/40 d 2/40 2/28 d 2/28
Pseudoaneurysm after open
repair
4/40 d 4/40 d 3/13 3/13
Aortic dissection 3/40 5/15 8/15 d 3/13 3/13
Cutaneous left subclavian
aneurysm ﬁstula
1/40 d 1/40 d d
Traumatic thoracic aortic
transection
d d d d 1/13 1/13
Mycotic TAA 1/40 2/15 3/15 d d
NR 20/40 d 20/40 12/28 d 12/28
Time interval, months, mean
(95% CI)
8.2 (6.7-9.6) 24.7 (9.2-40.2) 12.9 (8.2-17.7) 19.0 (2.7-35.3) 10.6 (2.1-19.1) 15.7 (5.6-25.8)
Clinical presentation
AEF 16 (14 d) 9 (7 d) 25 (21 d) 14 (7 d) 8 (5 d) 22 (12 d)
ABF 3 (3 d) 3 (2 d) 6 (5 d) 6 (3 d) 3 (1 d) 9 (4 d)
AEF and ABF 4 (4 d) 0 4 (4 d) 1 (0 d) 1 (1 d) 2 (1 d)
Constitutional symptoms 17 (15 d) 3 (0 d) 20 (15 d) 7 (2 d) 1 (0 d) 8 (2 d)
Additional therapy 15/18 (83.3%) 5/8 (62.5%) 20/26 (76.9%) d d d
Only antibiotics 21/22 (95.5%) 4/7 (57.1%) 25/29 (86.2%) d d d
In situ reconstruction d d d 25 (10d) 10 (5 d) 35 (15 d)
Extra-anatomic bypass d d d 3 (2 d) 3 (2 d) 6 (4 d)
In-hospital mortality 19/40 (47.5%) 4/15 (26.7%) 23/55 (41.8%) 8/28 (28.6%) 5/13 (38.5%) 13/41 (31.7%)
Follow-up, months, mean
(95% CI)
11 (4.1-17.9) 5.1 (1.9-8.4) 8.6 (4.4-12.9) 15.2 (7.5-22.9) 15.6 (4.4-26.7) 15.3 (9.4-21.3)
Overall aneurysm-related
mortality
36/40 (90%) 9/15 (60%) 45/55 (81.8%) 12/28 (42.8%) 7/13 (53.8%) 19/41 (46.3%)
ABF, Aortobronchial ﬁstula; AEF, aortoesophageal ﬁstula; CI, conﬁdence interval; F, female; M, male; NR, not recorded; TAA, thoracic aortic
aneurysm.
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Fig 3. Comparison of outcome in patients receiving antibiotic therapy vs antibiotic therapy followed by additional
procedures, such as mediastinal drainage, repeated thoracic endovascular aortic repair (TEVAR), and repair of the
ﬁstula. CI, Conﬁdence interval; Ev/Trt, events/treated with antibiotic therapy; Ev/Ctrl, events/control (antibiotics þ
additional procedures).
Fig 4. Comparison of outcome in ﬁstula patients (aortoesophageal ﬁstula [AEF] or aortobronchial ﬁstula [ABF]) vs
nonﬁstula patients. CI, Conﬁdence interval; Ev/Trt, events/treated for ﬁstula; Ev/Ctrl, events/control (nonﬁstula).
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mortality rate for patients treated with stent graft preserva-
tion and an overall mortality of 45% in the follow-up.41 We
had also found evidence for lower mortality in patients who
underwent an additional procedure, such as drainage, sur-
gical débridement, and sac irrigation, a ﬁnding that was
conﬁrmed in this study.41 Additional measures may control
or resolve the sepsis temporarily, but the infection cannot
be eradicated or cured without the excision of the infected
prosthetic material. Evaluating these results with a critical
view, it becomes evident that the option to preserve the
endograft and to treat the infection both locally and sys-
tematically, although appealing, has an extremely high
mortality rate and is not a viable and durable option. Itcan be offered to patients who refuse surgery and to
severely ill patients who are not candidates for more aggres-
sive surgery, such as explantation, as a palliative option. It
can also be considered as a bridging solution for septic he-
modynamically unstable patients until their general status is
improved.
It becomes also apparent from the present study that a
thoracic endograft infection resulting in contamination of
the mediastinum space is associated with a great magnitude
of systemic infections and poor outcomes. Endograft exci-
sion is a challenging operation with high morbidity and
mortality rates. Surgical conversion with endograft excision
and aortic reconstruction, in situ or with extra-anatomic
bypass, was associated in our study with a considerable
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challenge of reconstructing a severely damaged area
involving critical surrounding organs such as the esoph-
agus and the bronchial tree. Four more aneurysm-
related deaths were recorded in follow-up, leading to an
overall mortality of 46.3% and emphasizing the need of
continuing surveillance of these patients as infection
and ﬁstula may recur. The absence of a large series makes
comparisons of management options difﬁcult. We did not
detect a safe trend toward extra-anatomic bypass or in
situ aortic reconstruction.
The presence of ﬁstula has, on the one hand, the poten-
tial of acute bleeding and, on the other, the potential of
continuous contamination of the circulation with microor-
ganisms that put the patient in a constant septic condition.1
Communication between the aortic graft and an adjacent
organ will never be cured without the closure of the ﬁstula.
Antibiotic therapy may reduce or resolve sepsis temporarily,
but infection cannot be eradicated or cured without surgical
reconstruction. The presence of ﬁstula portends signiﬁcantly
worse prognosis.3,6-8 In our study, a considerable percent-
age (68 of 91) of patients with endograft infection presented
with aortic ﬁstula. The incidence of AEF or ABF is not negli-
gible after TEVAR. Chiesa et al have reported the larger
series of AEF and ABF after TEVAR. Eleven patients under-
went surgical treatment, with a perioperative mortality of
64%, and eight patients were treated conservatively, all of
whom died within 30 days.3 Our meta-analysis conﬁrmed
a trend of worse outcome, in terms of overall mortality,
for patients with ﬁstula compared with nonﬁstula patients.
This study has limitations. Because of the paucity of
large series, we reviewed all the reported studies including
case reports. Although publication bias may occur with the
inclusion of case reports, in our analysis, interestingly, case
reports included were associated predominantly with a
dismal outcome and did not shift the results, emphasizing
the devastating prognosis of this lethal disease. Besides,
there was a considerable lack of available data concerning
the indication for index TEVAR procedure, the comorbid-
ities, the clinical status of the patients at the time of endograft
infection diagnosis, and the isolated pathogens. Thus, a
further meta-regression analysis could not be performed.
In spite of considerable differences found in terms of descrip-
tive percentages, the meta-analysis showed a trend of better
outcome, in terms of overall mortality, with endograft
explantation comparedwith preservation and also conﬁrmed
a trend that the presence of ﬁstula was a predictor of death.
Furthermore, one could argue that group A patients prob-
ably were sicker overall and not candidates for open repair,
and vice versa. However, we undertook these separate
meta-analyses with the intention of investigating the impact
of the treatment option as well as the presence of a ﬁstula on
the outcome of these patients. We believe that the meta-
analysis would have reached statistical signiﬁcance with a
larger number of patients with the same qualitative charac-
teristics, but this is a hypothesis.However, aswasmentioned,
population-based studies or randomized trials are difﬁcult or
even unethical to organize.CONCLUSIONS
The treatment of infection after TEVAR with endograft
preservation seems not a durable and perspective option and
can be offered only to patients who refuse surgery or to old,
severely ill patients who are not candidates for more radical
surgical repair, as a palliative option or a bridging procedure.
Compared with antibiotic therapy alone, antibiotic therapy
associated with additional procedures, such as mediastinal
drainage, repeated TEVAR, and repair of the ﬁstula, may
control or resolve the sepsis, providing, however, mainly a
temporary beneﬁt. The presence of ﬁstula is a predictor of
dismal outcome. The gold standard of treatment for endog-
raft infection remains total endograft explantation with arte-
rial reconstruction, débridement, and repair of the ﬁstula if
present. The mortality rate of surgical conversion is much
higher in the presence of AEF or ABF.
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